WP
TARS icon

Woodline Partners’s Tarsus Pharmaceuticals TARS Stock Holding History

Woodline Partners’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.32M Hold
100,443
– – 0.02% 634
2026
Q1 		$7.05M Buy
100,443
+289
+0.3% +$20.2K 0.03% 592
2025
Q4 		$8.2M Hold
100,154
– – 0.03% 514
2025
Q3 		$5.95M Buy
100,154
+5
+0% +$246 0.03% 535
2025
Q2 		$4.06M Hold
100,149
– – 0.02% 603
2025
Q1 		$5.14M Sell
100,149
-8,837
-8% -$437K 0.03% 501
2024
Q4 		$6.03M Buy
108,986
+37,417
+52% +$1.7M 0.04% 447
2024
Q3 		$2.35M Buy
+71,569
New +$2.01M 0.02% 462
2021
Q2 		– Sell
-12,310
Closed -$397K – 629
2021
Q1 		$397K Buy
+12,310
New +$455K 0.01% 400

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners's TARS Position: Q2 2026 in Review

Woodline Partners held its Tarsus Pharmaceuticals (TARS) position steady in Q2 2026 at 100,443 shares worth $6.32M. The position accounts for 0.02% of the portfolio, ranked #634.

Woodline Partners first reported a position in TARS in Q1 2021 and has held it in 9 quarters since. The position peaked at $8.2M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Woodline Partners held 100,443 shares of Tarsus Pharmaceuticals worth $6.32M as of Q2 2026.
  • Woodline Partners left its Tarsus Pharmaceuticals share count unchanged in Q2 2026.
  • Tarsus Pharmaceuticals made up 0.02% of Woodline Partners's portfolio in Q2 2026, its #634 holding.
  • Woodline Partners first reported a position in Tarsus Pharmaceuticals in Q1 2021 and has held it in 9 quarters since.
  • Woodline Partners's Tarsus Pharmaceuticals position peaked at $8.2M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.